Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single‐center, open‐label study

K Chino, T Kondo, R Sakai, S Saito… - International Journal …, 2019 - Wiley Online Library
Objectives Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the elderly
of unknown etiology. While glucocorticoids are the mainstay of treatment for PMR, various …
被引用次数：27 相关文章

Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study

K Chino, T Kondo, R Sakai, S Saito… - International …, 2019 - pubmed.ncbi.nlm.nih.gov
Objectives Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the elderly
of unknown etiology. While glucocorticoids are the mainstay of treatment for PMR, various …

Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single‐center, open‐label study.

K Chino, T Kondo, R Sakai, S Saito… - International …, 2019 - search.ebscohost.com
Objectives: Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the elderly
of unknown etiology. While glucocorticoids are the mainstay of treatment for PMR, various …

Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study.

K Chino, T Kondo, R Sakai, S Saito… - … Journal of Rheumatic …, 2019 - europepmc.org
OBJECTIVES: Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the
elderly of unknown etiology. While glucocorticoids are the mainstay of treatment for PMR …

Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single‐center, open‐label study

K Chino, T Kondo, R Sakai, S Saito, Y Okada… - International Journal of …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Objectives</jats: title>< jats: p>
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the elderly of unknown …